Gilead Sciences [GILD] vs Johnson & Johnson [JNJ] Detailed Stock Comparison

Gilead Sciences, Inc.

NASDAQ
Loading...

Johnson & Johnson

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Gilead Sciences, Inc. wins in 9 metrics, Johnson & Johnson wins in 12 metrics, with 0 ties. Johnson & Johnson appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Gilead Sciences, Inc. Johnson & Johnson Better
P/E Ratio (TTM) 19.66 20.49 Gilead Sciences, Inc.
Price-to-Book Ratio 7.29 6.68 Johnson & Johnson
Debt-to-Equity Ratio 112.92 60.50 Johnson & Johnson
PEG Ratio 0.85 0.42 Johnson & Johnson
EV/EBITDA 12.44 16.84 Gilead Sciences, Inc.
Profit Margin (TTM) 28.90% 21.83% Gilead Sciences, Inc.
Operating Margin (TTM) 37.38% 26.72% Gilead Sciences, Inc.
EBITDA Margin (TTM) 37.38% 26.72% Gilead Sciences, Inc.
Return on Equity 40.66% 32.87% Gilead Sciences, Inc.
Return on Assets (TTM) 12.52% 13.46% Johnson & Johnson
Free Cash Flow (TTM) $9.46B $19.31B Johnson & Johnson
Dividend Yield 2.57% 2.09% Gilead Sciences, Inc.
1-Year Return 14.19% 53.32% Johnson & Johnson
Price-to-Sales Ratio (TTM) 5.62 5.66 Gilead Sciences, Inc.
Enterprise Value $181.31B $574.25B Johnson & Johnson
EV/Revenue Ratio 6.16 5.96 Johnson & Johnson
Gross Profit Margin (TTM) 79.51% 67.56% Gilead Sciences, Inc.
Revenue per Share (TTM) $24 $40 Johnson & Johnson
Earnings per Share (Diluted) $6.78 $11.04 Johnson & Johnson
Beta (Stock Volatility) 0.40 0.33 Johnson & Johnson
Short % of Float 1.74% 1.03% Johnson & Johnson

Gilead Sciences, Inc. vs Johnson & Johnson Stock Performance Analysis

Loading Price Chart...

GILD
JNJ

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Gilead Sciences, Inc.-1.03%-2.97%-4.07%-14.40%3.77%2.22%
Johnson & Johnson-2.16%1.51%3.95%-3.10%10.03%13.65%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Gilead Sciences, Inc.14.19%59.26%88.55%51.95%535.26%767.93%
Johnson & Johnson53.32%46.67%48.70%108.58%263.36%290.52%

Performance & Financial Health Analysis: Gilead Sciences, Inc. vs Johnson & Johnson

MetricGILDJNJ
Market Information
Market Cap i$165.87B$555.84B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i4,914,2128,370,566
90 Day Avg. Volume i5,711,5647,752,965
Last Close$124.30$235.66
52 Week Range$104.46 - $157.29$149.04 - $251.71
% from 52W High-20.97%-6.38%
All-Time High$157.27 (Feb 11, 2026)$251.71 (Mar 02, 2026)
% from All-Time High-20.96%-6.38%
Growth Metrics
Quarterly Revenue Growth0.05%0.10%
Quarterly Earnings Growth0.22%-0.52%
Financial Health
Profit Margin (TTM) i0.29%0.22%
Operating Margin (TTM) i0.37%0.27%
Return on Equity (TTM) i0.41%0.33%
Debt to Equity (MRQ) i112.9260.50
Cash & Liquidity
Book Value per Share (MRQ)$18.29$33.87
Cash per Share (MRQ)$7.74$8.34
Operating Cash Flow (TTM) i$10.02B$22.21B
Levered Free Cash Flow (TTM) i$7.54B$43.47B
Dividends
Last 12-Month Dividend Yield i2.57%2.09%
Last 12-Month Dividend i$3.98$5.20

Valuation & Enterprise Metrics Analysis: Gilead Sciences, Inc. vs Johnson & Johnson

MetricGILD (Apr 24, 2026)JNJ (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i19.6620.49
Forward P/E i13.8517.80
PEG Ratio i0.850.42
Price to Sales (TTM) i5.625.66
Price to Book (MRQ) i7.296.68
Market Capitalization
Market Capitalization i$165.87B$555.84B
Enterprise Value i$181.31B$574.25B
Enterprise Value Metrics
Enterprise to Revenue i6.165.96
Enterprise to EBITDA i12.4416.84
Risk & Other Metrics
Beta i0.400.33
Book Value per Share (MRQ) i$18.29$33.87

Financial Statements Comparison: Gilead Sciences, Inc. vs Johnson & Johnson

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGILD (2025)JNJ (2025)
Revenue/Sales i29.44B94.19B
Cost of Goods Sold i6.23B30.26B
COGS % of Revenue i21.2%32.1%
Gross Profit i23.21B63.94B
Gross Margin i78.8%67.9%
Research & Development i5.80B14.67B
Operating Income (EBIT) i11.70B25.60B
Operating Margin i39.7%27.2%
EBITDA i14.81B35.16B
EBITDA Margin i50.3%37.3%
Pre-Tax Income i9.80B32.58B
Pre-Tax Income % of Revenue i33.3%34.6%
Income Tax i1.29B5.78B
Income Tax % of Revenue i4.4%6.1%
Net Income (Profit) i8.51B26.80B
Profit Margin i28.9%28.5%

Balance Sheet & Liquidity Metrics

MetricGILD (2025)JNJ (2025)
Cash & Equivalents i7.56B19.71B
Total Current Assets i18.34B55.62B
Total Current Assets % of Revenue i62.3%59.1%
Total Current Liabilities i11.81B54.13B
Total Current Liabilities % of Revenue i40.1%57.5%
Long-Term Debt i22.13B39.44B
Long-Term Debt % of Revenue i75.2%41.9%
Total Shareholders Equity i22.62B81.54B
Retained Earnings i13.73BN/A
Retained Earnings % of Revenue i46.6%0.0%
Property, Plant & Equipment i1.71B0

Cash Flow Statement Comparison

MetricGILD (2025)JNJ (2025)
Operating Cash Flow i10.19B22.21B
Operating Cash Flow % of Revenue i34.6%23.6%
Capital Expenditures i-563.00M-4.83B
Free Cash Flow i9.46B19.31B
FCF Margin i32.1%20.5%
Debt Repayment i-1.79B-14.09B
Common Stock Repurchase i-1.92B-5.95B

Short Interest & Institutional Ownership Analysis

MetricGILDJNJ
Shares Short i21.52M22.27M
Short Ratio i3.562.90
Short % of Float i1.74%1.03%
Shares Outstanding i1.24B2.41B
Float Shares i1.24B2.41B
% Held by Insiders i0.13%0.06%
% Held by Institutions i92.71%75.84%
% Held by Public i7.16%24.10%

Dividend Analysis & Yield Comparison: Gilead Sciences, Inc. vs Johnson & Johnson

MetricGILDJNJ
Last 12-Month Dividend i$3.98$5.20
Last 12-Month Dividend Yield i2.57%2.09%
3-Year Avg Annual Dividend i$3.35$4.97
3-Year Avg Dividend Yield i0.85%0.74%
3-Year Total Dividends i$10.06$14.92
Ex-Dividend DateMar 13, 2026Feb 24, 2026